Crinetics Pharmaceuticals (CRNX) Operating Income (2017 - 2025)
Historic Operating Income for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$142.6 million.
- Crinetics Pharmaceuticals' Operating Income fell 6240.42% to -$142.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$477.8 million, marking a year-over-year decrease of 5576.9%. This contributed to the annual value of -$338.9 million for FY2024, which is 5222.0% down from last year.
- According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Operating Income is -$142.6 million, which was down 6240.42% from -$129.1 million recorded in Q2 2025.
- Crinetics Pharmaceuticals' Operating Income's 5-year high stood at -$22.9 million during Q1 2021, with a 5-year trough of -$142.6 million in Q3 2025.
- Over the past 5 years, Crinetics Pharmaceuticals' median Operating Income value was -$56.0 million (recorded in 2023), while the average stood at -$66.3 million.
- As far as peak fluctuations go, Crinetics Pharmaceuticals' Operating Income tumbled by 2311.53% in 2023, and later crashed by 6240.42% in 2025.
- Over the past 5 years, Crinetics Pharmaceuticals' Operating Income (Quarter) stood at -$30.9 million in 2021, then plummeted by 53.96% to -$47.6 million in 2022, then tumbled by 31.76% to -$62.7 million in 2023, then plummeted by 51.21% to -$94.7 million in 2024, then tumbled by 50.49% to -$142.6 million in 2025.
- Its last three reported values are -$142.6 million in Q3 2025, -$129.1 million for Q2 2025, and -$111.4 million during Q1 2025.